UPDATE : Tuesday, November 20, 2018
HOME Pharma
Local novel drugs achieve rapid growth in Q3
  • By So Jae-hyeon
  • Published 2017.12.07 11:53
  • Updated 2017.12.07 11:53
  • comments 0

Novel drugs by local drugmakers achieved a rapid sales growth in the third quarter, industry data showed Thursday.

According to data from IMS Health, a U.S. information provider for the healthcare industry, 12 local new drugs posted 116.02 billion won ($106.7 million) in accumulated sales by the third quarter this year, up 25 percent from 92.81 billion won a year earlier.

Since the first approval of the new drug for SK Chemical’s Sunpla Injection in 1999, the domestic pharmaceutical industry has released 29 novel drugs to date.

The No.1 novel drug in accumulated sales by the third quarter this year is LG Chem’s Zemimet, a combo drug for treating diabetes. The accumulated revenue of the drug rose to 28.86 billion won by the third quarter, soaring by 57.2 percent from 17.72 billion won a year earlier.

The company’s Zemiglo, a single treatment for diabetes, also saw a 17.2 percent growth in accumulated sales, posting 18.28 billion won by the third quarter. The accumulated revenues from the two drugs have topped 40 billion won.

Boryung Pharmaceutical’s hypertension treatment Kanarb is also performing well. Although its accumulated sales in single drugs fell by 12.5 percent year-on-year to post 22.7 billion won by the third quarter, combo therapy Dukarb’s robust revenue helped the company offset the decline. Dukarb’s accumulated sales amounted to 6.27 billion won by the third quarter, skyrocketing from 6 million won a year earlier.

Il-yang Pharm’s Noltec, an anti-ulcer drug, saw its accrued sales exceeding 10 billion won mark in the first three quarters. While the company is pushing to expand the drug’s indications, its accumulated sales reached 11.79 billion won in the third nine months of this year, up 25.8 percent from 9.37 billion won a year earlier.

Chong Kun Dang’s Duvie, an anti-diabetic drug in the thiazolidinedione (TZD) class, achieved 8.87 billion won in accumulated sales by the third quarter, up 10.9 percent from 7.99 billion won a year ago.

Daewoong Pharmaceutical’s Pelubi is also on the rise in sales. The treatment for osteoarthritis saw its accumulated revenue increase by 31.3 percent year-on-year to 4.94 billion won by the third quarter. The drug received approval from the Ministry of Food and Drug Safety in 2007.

Dong-A ST’s erectile dysfunction treatment Zydena posted 4.53 billion won in accumulated sales by the third quarter, CrystalGenomics’ osteoarthritis drug Acelex, 3.67 billion won, and Il-yang’s Supect 3.03 billion won, respectively.

“Local new drugs’ revenues rose, as they target chronic diseases such as diabetes and hypertension,” an industry official said. “Going forward, the market for biosimilar and oncological drugs will expand. Enhanced recognition of Korean brands through rising sales will help drugmakers compete in the high-end drug market, too.”


<© Korea Biomedical Review, All rights reserved.>

Other articles by So Jae-hyeon
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top